These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18293380)

  • 41. Is chronic use of hydroxyurea safe for patients with sickle cell anemia? An account of genotoxicity and mutagenicity.
    Maia Filho PA; Pereira JF; Almeida Filho TP; Cavalcanti BC; Sousa JC; Lemes RPG
    Environ Mol Mutagen; 2019 Apr; 60(3):302-304. PubMed ID: 30525240
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Optimizing hydroxyurea therapy for sickle cell anemia.
    Ware RE
    Hematology Am Soc Hematol Educ Program; 2015; 2015():436-43. PubMed ID: 26637755
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Hydroxyurea effectiveness in children and adolescents with sickle cell anemia: A large retrospective, population-based cohort.
    Quarmyne MO; Dong W; Theodore R; Anand S; Barry V; Adisa O; Buchanan ID; Bost J; Brown RC; Joiner CH; Lane PA
    Am J Hematol; 2017 Jan; 92(1):77-81. PubMed ID: 27761932
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Expanding the role of hydroxyurea in children with sickle cell disease.
    Rogers ZR; Buchanan GR
    J Pediatr; 2004 Sep; 145(3):287-8. PubMed ID: 15343174
    [No Abstract]   [Full Text] [Related]  

  • 45. Prevention of secondary stroke and resolution of transfusional iron overload in children with sickle cell anemia using hydroxyurea and phlebotomy.
    Ware RE; Zimmerman SA; Sylvestre PB; Mortier NA; Davis JS; Treem WR; Schultz WH
    J Pediatr; 2004 Sep; 145(3):346-52. PubMed ID: 15343189
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Hydroxyurea for Sickle Cell Disease: Now Is the Time!
    Strouse JJ
    South Med J; 2016 Sep; 109(9):535-7. PubMed ID: 27598356
    [No Abstract]   [Full Text] [Related]  

  • 47. Hydroxyurea therapy for sickle cell disease in Britain. Disappointing recruitment despite promising results.
    Olujohungbe A; Cinkotai KI; Yardumian A
    BMJ; 1998 Jun; 316(7146):1689. PubMed ID: 9614013
    [No Abstract]   [Full Text] [Related]  

  • 48. Managing acute chest syndrome of sickle cell disease in an African setting.
    Fawibe AE
    Trans R Soc Trop Med Hyg; 2008 Jun; 102(6):526-31. PubMed ID: 18455745
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Emerging drugs for sickle cell anemia.
    Singh PC; Ballas SK
    Expert Opin Emerg Drugs; 2015 Mar; 20(1):47-61. PubMed ID: 25431087
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Effectiveness and Safety of Hydroxyurea in the Treatment of Sickle Cell Anaemia Children in Jos, North Central Nigeria.
    Ofakunrin AOD; Oguche S; Adekola K; Okpe ES; Afolaranmi TO; Diaku-Akinwumi IN; Zoakah AI; Sagay AS
    J Trop Pediatr; 2020 Jun; 66(3):290-298. PubMed ID: 31608959
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Hydroxyurea marketed for sickle cell anemia.
    Am J Health Syst Pharm; 1998 May; 55(9):875. PubMed ID: 9588244
    [No Abstract]   [Full Text] [Related]  

  • 52. Hospitalization rates and costs of care of patients with sickle-cell anemia in the state of Maryland in the era of hydroxyurea.
    Lanzkron S; Haywood C; Segal JB; Dover GJ
    Am J Hematol; 2006 Dec; 81(12):927-32. PubMed ID: 16924648
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The impact of hydroxyurea on career and employment of patients with sickle cell anemia.
    Ballas SK; Bauserman RL; McCarthy WF; Waclawiw MA;
    J Natl Med Assoc; 2010 Nov; 102(11):993-9. PubMed ID: 21141286
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial.
    McGann PT; Flanagan JM; Howard TA; Dertinger SD; He J; Kulharya AS; Thompson BW; Ware RE;
    Pediatr Blood Cancer; 2012 Aug; 59(2):254-7. PubMed ID: 22012708
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rationale and design of mDOT-HuA study: a randomized trial to assess the effect of mobile-directly observed therapy on adherence to hydroxyurea in adults with sickle cell anemia in Tanzania.
    Makubi A; Sasi P; Ngaeje M; Novelli EM; Mmbando BP; Gladwin MT; Makani J
    BMC Med Res Methodol; 2016 Oct; 16(1):140. PubMed ID: 27756209
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Medical Neglect by Underprescription and Underutilization of Hydroxyurea in Children with Sickle Cell Disease.
    Rana S
    South Med J; 2016 Sep; 109(9):503-5. PubMed ID: 27598349
    [No Abstract]   [Full Text] [Related]  

  • 57. [Effectiveness and acceptance of hydroxyurea in the treatment of severe forms of sickle cell disease: a prospective study of 65 cases].
    Mellouli F; Chouaibi S; Dhouib N; Ouederni M; Ben Khaled M; Abbes S; Bejaoui M
    Tunis Med; 2013; 91(8-9):544-50. PubMed ID: 24227514
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Hydroxyurea in the treatment of sickle-cell anemia.
    Howard LW; Kennedy LD
    Ann Pharmacother; 1997 Nov; 31(11):1393-6. PubMed ID: 9391697
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Hydroxyurea use in patients with sickle cell disease in a Medicaid population.
    Ritho J; Liu H; Hartzema AG; Lottenberg R
    Am J Hematol; 2011 Oct; 86(10):888-90. PubMed ID: 21922530
    [No Abstract]   [Full Text] [Related]  

  • 60. Hydroxyurea in very young children with sickle cell anemia is not a cure-all.
    Powars DR
    J Pediatr; 2001 Dec; 139(6):763-4. PubMed ID: 11743496
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.